Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Registration Number
- NCT00873223
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
- Diagnosed with type 2 diabetes
- BMI less than 45.0 kg/m2
- Insulin naive
- Currently treated with Oral Anti-Diabetic drugs (OADs) and metformin with a HbA1c between 7.0 and 9.5% or currently treated with metformin only with a HbA1c between 7.0 and 10.0%
Exclusion Criteria
- Any clinically significant disease other than type 2 diabetes
- Currently using daily insulin
- Thiazolidinione use or other injectable diabetes medications within the last 3 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description A liraglutide - A insulin detemir -
- Primary Outcome Measures
Name Time Method Insulin detemir pharmacokinetics with and without liraglutide administration at approx. 12 weeks (including screening, washout and evaluation period)
- Secondary Outcome Measures
Name Time Method Pharmacokinetics of liraglutide with and without insulin detemir at approx. 12 weeks (including screening, washout and evaluation period)
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇺🇸Chula Vista, California, United States